---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-068301"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-06-06T23:59:59+00:00"
generated_at: "2026-06-25T04:26:09.440771+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA Phase 1 HB-200 shows 80% disease control with alternating 2-vector; Phase 2 initiated

## Summary
- Alternating 2-vector HB-202/HB-201 achieved 80% disease control rate vs historical 35-40% for pembrolizumab.
- 56% of alternating 2-vector patients had target lesion shrinkage vs 38% for single-vector HB-201.
- 32% on alternating 2-vector had tumor-specific T cells >5% of circulating pool vs 7% on HB-201.
- HB-200 well tolerated; only 8.8% grade ≥3 treatment-related side effects, mostly flu-like symptoms.
- Phase 2 plans include combos with pembrolizumab; initial results expected H2 2022, randomized trial H1 2023.

## SEC filing metadata
- accession: 0001104659-22-068301
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000110465922068301/0001104659-22-068301-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000110465922068301/tm2217741d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-068301
- JSON: https://secwatch.observer/filing/0001104659-22-068301.json
- Plain text: https://secwatch.observer/filing/0001104659-22-068301.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.